These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26208924)

  • 1. Pharmaceutical regulation in Europe and its impact on corporate R&D.
    Eger S; Mahlich JC
    Health Econ Rev; 2014 Dec; 4(1):23. PubMed ID: 26208924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment.
    Shaikh M; Del Giudice P; Kourouklis D
    Appl Health Econ Health Policy; 2021 Mar; 19(2):217-229. PubMed ID: 32666383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon performance, company financial performance, financial value, and transmission channel: an analysis of South African listed companies.
    Ganda F
    Environ Sci Pollut Res Int; 2022 Apr; 29(19):28166-28179. PubMed ID: 34988814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does chief executive compensation predict financial performance or inaccurate financial reporting in listed companies: A systematic review.
    Rousseau D; Kim BJ; Splenda R; Young S; Lee J; Beck D
    Campbell Syst Rev; 2023 Dec; 19(4):e1370. PubMed ID: 38089569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study.
    Hughes DA; Poletti-Hughes J
    PLoS One; 2016; 11(10):e0164681. PubMed ID: 27768685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E; Kim TH; Jeung MJ; Lee EK
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can R&D investment reduce the impact of COVID-19 on firm performance?-Evidence from India.
    Biswas S
    J Public Aff; 2021 Oct; ():e2773. PubMed ID: 34899063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing Reimbursement Drug Price Risk to Enhance R&D Incentives without Raising Drug Prices/Expenditures: Implications of Simulations Based on Questionnaire Survey of Pharmaceutical Companies in Japan.
    Nakamura H; Wakutsu N
    Health Policy; 2020 Jul; 124(7):714-720. PubMed ID: 32475740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of corporate charitable giving on hospitality firm performance: Doing well by doing good?
    Chen MH; Lin CP
    Int J Hosp Manag; 2015 May; 47():25-34. PubMed ID: 32287861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The COVID-19 outbreak and corporate cash-holding levels: Evidence from China.
    Zhou D; Zhou H; Bai M; Qin Y
    Front Psychol; 2022; 13():942210. PubMed ID: 36324775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of ESGC Indicators on Financial Performance of Listed Pharmaceutical Companies.
    López-Toro AA; Sánchez-Teba EM; Benítez-Márquez MD; Rodríguez-Fernández M
    Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33923122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea.
    Lee M
    Osong Public Health Res Perspect; 2015 Aug; 6(4):249-55. PubMed ID: 26473092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R&D implementation in a department of laboratory medicine and pathology: a systematic review based on pharmaceutical companies.
    Feulefack J; Sergi C
    Glob J Health Sci; 2015 Jan; 7(4):70-82. PubMed ID: 25946935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corporate capital structure effects on corporate performance pursuing a strategy of innovation in manufacturing companies.
    Ahmed F; Rahman MU; Rehman HM; Imran M; Dunay A; Hossain MB
    Heliyon; 2024 Feb; 10(3):e24677. PubMed ID: 38322932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the randomized controlled drug trial in Europe lagging behind the USA?
    Lambers Heerspink HJ; Knol MJ; Tijssen RJ; van Leeuwen TN; Grobbee DE; de Zeeuw D
    Br J Clin Pharmacol; 2008 Dec; 66(6):774-80. PubMed ID: 19032722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the R&D Expenditure of Listed Companies Green? Evidence from China's A-Share Market.
    Li B; Li L; Pi T
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
    Ozieranski P; Martinon L; Jachiet PA; Mulinari S
    Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the impact of external collaboration on firm growth capability: the mediating roles of R&D efforts.
    Chen S; Yu D
    Humanit Soc Sci Commun; 2022; 9(1):404. PubMed ID: 36373149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.